Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals
Benzinga · 2d ago
Share
Listen to the news
ICOTYDE clinical data highlights2
- High levels of skin clearance were observed at Week 112, with ≥72% of ICOTYDE-treated patients achieving a Psoriasis Area and Severity Index score (PASI)c of 90 and ≥70% achieving clear or almost clear skin (Investigator's Global Assessment [IGA]d 0/1) from Week 64 through Week 112.
- Complete skin clearance was sustained from Week 64 through Week 112, with ≥44% of ICOTYDE-treated patients achieving PASI 100 and ≥46% achieving IGA 0 (clear skin).
- Clinically meaningful improvement in itch was sustained in 78% of patients from Week 64 to Week 112.
- Among PASI 90 responders who were withdrawn from ICOTYDE at Week 24, 85% regained PASI 90 response within 24 weeks of retreatment.
- Safety findings through Week 112 remained consistent with the established safety profile of ICOTYDE, with no new safety signals identified.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved